QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 guggenheim-downgrades-deciphera-pharmaceuticals-to-neutral

Guggenheim analyst Michael Schmidt downgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Buy to Neutral.

 jmp-securities-downgrades-deciphera-pharmaceuticals-to-market-perform

JMP Securities analyst Reni Benjamin downgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Market Outperform to Market Per...

 barclays-upgrades-deciphera-pharmaceuticals-to-equal-weight-raises-price-target-to-26

Barclays analyst Peter Lawson upgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Underweight to Equal-Weight and raises t...

 us-stocks-kick-off-the-week-in-the-green-tesla-rockets-on-chinas-fsd-approval-yen-rallies-whats-driving-markets-monday

U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events...

 why-is-cancer-focused-deciphera-pharmaceuticals-stock-skyrocketing-on-monday

ONO Pharmaceutical to acquire Deciphera Pharmaceuticals for $2.4B in cash. Deciphera brings specialized R&D in kinase drug ...

 jonestrading-downgrades-deciphera-pharmaceuticals-to-hold-announces-256-price-target

JonesTrading analyst Soumit Roy downgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Buy to Hold and announces $25.6 pric...

 jefferies-downgrades-deciphera-pharmaceuticals-to-hold-lowers-price-target-to-256

Jefferies analyst Eun Yang downgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Buy to Hold and lowers the price target f...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION